Endogenous hypercortisolism inducing reversible ocular hypertension.
Cushing's syndrome
Endogenous hypercortisolism
Glaucoma
Glucocorticoid
Ocular hypertension
Trabecular meshwork
Journal
American journal of ophthalmology case reports
ISSN: 2451-9936
Titre abrégé: Am J Ophthalmol Case Rep
Pays: United States
ID NLM: 101679941
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
28
02
2019
revised:
10
09
2019
accepted:
05
11
2019
entrez:
27
11
2019
pubmed:
27
11
2019
medline:
27
11
2019
Statut:
epublish
Résumé
To describe the clinical findings of two patients with reversible ocular hypertension secondary to endogenous hypercortisolism. Retrospective, observational case series. A 65-year-old man (patient 1) and a 21-year-old woman (patient 2) were both found to have Cushing's syndrome after presentation to our clinic with elevated intraocular pressures (IOP). Clinical histories, ophthalmic examinations including IOP measurements, optical coherence tomography of the retinal nerve fiber layer, visual field testing, magnetic resonance imaging and computerized tomography of two patients were reviewed between 2007 and 2019. Patient 1 demonstrated elevated IOP (maximum 26 mmHg OD and 22 mmHg OS) and bilateral disc edema. Following diagnosis of Cushing's syndrome, the patient underwent two pituitary resections and bilateral adrenalectomy, with subsequent resolution of his hypercortisolism and ocular hypertension (OHT). Patient 2 presented with blurred vision and found to have OHT (maximum 32 mmHg OU). Following diagnosis of Cushing's disease and two resections of her adrenocorticotropic hormone (ACTH) producing pituitary adenoma, her IOPs normalized. Both patients maintained normal IOPs after resolution of their endogenous hypercortisolism and discontinuation of topical IOP-lowering medication. Ocular hypertension induced by endogenous hypercortisolism is, in some cases, fully reversible following normalization of cortisol levels. These findings suggest that the physiologic changes to the trabecular meshwork induced by endogenous hypercortisolism may be fully reversible.
Identifiants
pubmed: 31768472
doi: 10.1016/j.ajoc.2019.100573
pii: S2451-9936(19)30098-2
pii: 100573
pmc: PMC6872801
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100573Subventions
Organisme : NEI NIH HHS
ID : P30 EY010572
Pays : United States
Informations de copyright
© 2019 The Authors.
Déclaration de conflit d'intérêts
The following authors have no financial disclosures: SG, TB, BE, WH, MG, ST.
Références
Invest Ophthalmol Vis Sci. 1997 Aug;38(9):1902-7
pubmed: 9286282
Am J Pathol. 2017 Apr;187(4):713-723
pubmed: 28167045
Arch Ophthalmol. 1972 Apr;87(4):369-77
pubmed: 5018239
Am J Ophthalmol. 1951 Dec;34(12):1675-86
pubmed: 14894574
Eye (Lond). 2000 Jun;14 ( Pt 3B):429-36
pubmed: 11026970
J Ocul Pharmacol. 1994 Spring;10(1):385-91
pubmed: 8207341
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5412-8
pubmed: 18719086
Invest Ophthalmol Vis Sci. 1991 Apr;32(5):1600-8
pubmed: 2016141
Exp Eye Res. 2015 Dec;141:15-22
pubmed: 26051991
Sci Rep. 2018 Jan 16;8(1):862
pubmed: 29339763
Lancet. 1984 Apr 7;1(8380):767-8
pubmed: 6143086
Invest Ophthalmol Vis Sci. 1994 Jan;35(1):281-94
pubmed: 8300356
Exp Eye Res. 2009 Apr;88(4):752-9
pubmed: 18977348
Am J Ophthalmol. 1988 Nov 15;106(5):607-12
pubmed: 3189477
Am J Med Sci. 1966 Aug;252(2):239-44
pubmed: 5332356
Ann Ocul (Paris). 1954 Sep;187(9):805-16
pubmed: 13218439
Curr Eye Res. 1993 Sep;12(9):783-93
pubmed: 8261790
Invest Ophthalmol Vis Sci. 1985 Feb;26(2):170-5
pubmed: 4038695
Arch Ophthalmol. 1962 Dec;68:742-53
pubmed: 13967694
Am J Ophthalmol. 1964 Apr;57:543-51
pubmed: 14139296
Am J Ophthalmol. 1975 Jun;79(6):1012-7
pubmed: 1173539
Exp Clin Endocrinol Diabetes. 2011 Jan;119(1):21-5
pubmed: 20827660
Am J Ophthalmol. 1974 Sep;78(3):497-500
pubmed: 4413577
Invest Ophthalmol Vis Sci. 2003 Feb;44(2):473-85
pubmed: 12556371
Arch Ophthalmol. 1963 Oct;70:492-9
pubmed: 14078871
N Engl J Med. 2017 Apr 13;376(15):1451-1459
pubmed: 28402781
Mol Cell Biol. 2004 Oct;24(20):9019-25
pubmed: 15456875